Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ampelopsin (also known as dihydromyricetin) is a flavonoid compound primarily found in the plant Ampelopsis grossedentata. There is emerging scientific evidence suggesting its potential role in supporting or treating osteoporosis, although this research is mostly preclinical and not yet established in clinical practice. Several animal studies have shown that ampelopsin can positively influence bone metabolism. For example, research in ovariectomized rats (a common model for postmenopausal osteoporosis) has demonstrated that ampelopsin supplementation can increase bone mineral density, suppress bone resorption, and enhance bone formation. The proposed mechanisms include the inhibition of osteoclastogenesis (bone-resorbing cells) and the stimulation of osteoblast activity (bone-forming cells), possibly through modulation of oxidative stress and inflammatory pathways. However, there are currently no large-scale human clinical trials validating its effectiveness or safety in osteoporosis patients. The evidence is promising but limited to laboratory and animal studies, making the evidence moderate but far from conclusive. In summary, while ampelopsin is not a traditional remedy for osteoporosis, there is scientific rationale and early-stage preclinical evidence supporting its potential benefit. More rigorous human studies are needed before it can be recommended as a treatment for osteoporosis.

More about ampelopsin
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by ampelopsin

Products containing ampelopsin